Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany.
Research Group Clinical Neuroendocrinology, Max Planck Institute of Psychiatry, Munich, Germany.
Eur J Endocrinol. 2021 Jul 1;185(2):231-239. doi: 10.1530/EJE-21-0178.
Patients with craniopharyngioma (CP) frequently suffer from morbid obesity. Endocannabinoids (ECs) are involved in weight gain and rewarding behavior but have not been investigated in this context.
Cross-sectional single-center study.
Eighteen patients with CP and 16 age- and sex-matched controls were included. Differences in endocannabinoids (2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (AEA)) and endocannabinoid-like molecules (oleoyl ethanolamide (OEA), palmitoylethanolamide (PEA), and arachidonic acid (AA) were measured at baseline and following endurance exercise. We further explored ECs-dynamics in relation to markers of HPA-axis activity (ACTH, cortisol, copeptin) and hypothalamic damage.
Under resting conditions, independent of differences in BMI, 2-AG levels were more than twice as high in CP patients compared to controls. In contrast, 2-AG and OEA level increased in response to exercise in controls but not in CP patients, while AEA levels decreased in controls. As expected, exercise increased ACTH and copeptin levels in controls only. In a mixed model analysis across time and group, HPA measures did not provide additional information for explaining differences in 2-AG levels. However, AEA levels were negatively influenced by ACTH and copeptin levels, while OEA levels were negatively predicted by copeptin levels only. There were no significant differences in endocannabinoids depending on hypothalamic involvement.
Patients with CP show signs of a dysregulated endocannabinoid system under resting conditions as well as following exercise in comparison to healthy controls. Increased 2-AG levels under resting conditions and the missing response to physical activity could contribute to the metabolic phenotype of CP patients.
颅咽管瘤(CP)患者常患有病态肥胖。内源性大麻素(ECs)参与体重增加和奖赏行为,但尚未在这方面进行研究。
横断面单中心研究。
纳入 18 例 CP 患者和 16 例年龄和性别匹配的对照者。在基线和耐力运动后测量内源性大麻素(2-花生四烯酸甘油(2-AG)和 N-花生四烯酸乙醇胺(AEA))和内源性大麻素样分子(油酰乙醇酰胺(OEA)、棕榈酰乙醇酰胺(PEA)和花生四烯酸(AA)的差异。我们进一步探讨了 ECs 动力学与 HPA 轴活性(ACTH、皮质醇、copeptin)和下丘脑损伤标志物的关系。
在静息状态下,无论 BMI 差异如何,CP 患者的 2-AG 水平是对照组的两倍以上。相比之下,2-AG 和 OEA 水平在对照组中运动后增加,但在 CP 患者中没有增加,而 AEA 水平在对照组中下降。如预期的那样,运动仅增加了对照组的 ACTH 和 copeptin 水平。在跨时间和组的混合模型分析中,HPA 测量并不能为解释 2-AG 水平差异提供额外信息。然而,AEA 水平受到 ACTH 和 copeptin 水平的负向影响,而 OEA 水平仅受到 copeptin 水平的负向预测。内源性大麻素水平不受下丘脑受累的影响。
与健康对照组相比,CP 患者在静息状态下以及运动后均表现出内源性大麻素系统失调的迹象。静息状态下 2-AG 水平升高和对体力活动的反应缺失可能是 CP 患者代谢表型的原因。